Avity Investment Management Inc. Has $20.76 Million Stock Holdings in Boston Scientific Corporation $BSX

Avity Investment Management Inc. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 34.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 217,749 shares of the medical equipment provider’s stock after purchasing an additional 55,223 shares during the period. Avity Investment Management Inc.’s holdings in Boston Scientific were worth $20,762,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter valued at about $26,000. Steph & Co. bought a new stake in shares of Boston Scientific during the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp increased its holdings in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Financial Consulate Inc. bought a new position in Boston Scientific in the 3rd quarter worth approximately $25,000. Finally, United Community Bank raised its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Goldman Sachs trimmed its price target from $98 to $93 but kept a “buy” rating, which signals continued institutional confidence and still implies material upside from current levels. Goldman Sachs price target note
• Neutral Sentiment: Coverage/valuation context: a recent writeup notes analysts are tightening growth/execution assumptions and modestly lowering fair‑value estimates, reflecting a gradual reset rather than a structural change in the business. Why The Narrative Around Boston Scientific Is Shifting
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS forecast very slightly (from $3.92 to $3.91), a minor estimate tweak that suggests analysts are incrementally lowering near‑term assumptions but not cutting guidance aggressively. Erste Group estimate update
• Negative Sentiment: A broad flurry of law firms and investor‑rights groups (Glancy Prongay Wolke & Rotter, The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Portnoy, Bernstein Liebhard and others) have issued class‑action notices and investor alerts alleging misrepresentations tied to the July 23, 2025–Feb 3, 2026 class period; they’re soliciting lead‑plaintiff candidates with a May 4, 2026 deadline — the sheer volume of filings/alerts is creating headline pressure and increases the risk of litigation expense, management distraction, and potential settlement/awards. Representative notices: PR Newswire – Glancy notice GlobeNewsWire – Gross Law Firm Newsfile – Faruqi & Faruqi

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Morgan Stanley lowered their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. TD Cowen lowered their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. UBS Group dropped their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Finally, Canaccord Genuity Group reduced their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus price target of $106.00.

Boston Scientific Price Performance

NYSE BSX opened at $69.21 on Friday. Boston Scientific Corporation has a 12-month low of $67.56 and a 12-month high of $109.50. The firm’s 50 day moving average is $77.45 and its 200-day moving average is $90.83. The company has a market capitalization of $102.86 billion, a PE ratio of 35.68, a price-to-earnings-growth ratio of 1.08 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the firm earned $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.